|
|
|
|
About Us:
Gary R. Burleson, Ph.D. CEO/President Dr. Burleson has over 25 years professional experience in academia, clinical, contract research, government, and the pharmaceutical industry. This experience includes academic appointments and affiliations at the University of Notre Dame and North Carolina State University; clinical experience at Milwaukee County General Hospital; contract research organization experience; government regulatory experience at the U.S. Environmental Protection Agency (USEPA); and pharmaceutical experience in drug discovery at Procter & Gamble. Dr. Burleson has scientific expertise in the following broad areas: Immunotoxicology, Microbiology, Immunology, Virology, Clinical Microbiology, Pulmonary Immunology, Tumor Metastasis, Immunomodulation, Inflammation, and Computer Disease Modeling.
Florence G. Burleson, Ph.D. Executive VP - Director, Laboratory Operations
Dr. Burleson has over 15 years professional experience including: Study Director for GLP compliant studies for pharmaceutical clients; host resistance studies for pharmaceutical clients; immunoassay development (ELISA) and application to large clinical trial analyses; cytokine production as detected by PCR & RT-PCR; irritancy and hypersensitivity assays, i.e., LLNA; pharmacogenomics and genetic susceptibility tests; and interferon bioassay. Dr. Burleson has government experience at the National Institute of Environmental Health Sciences and pharmaceutical experience at Procter & Gamble. The author of a Virology text published by Academic Press, Dr. Burleson has taught and has a faculty appointment at North Carolina State University.
Rodney R. Dietert, Ph.D. Director, Developmental Immunotoxicology
Dr. Dietert is Consulting Director of Developmental Immunotoxicology at BRT and Professor of Immunotoxicology in the Department of Microbiology and Immunology at Cornell University. He has 29 years experience in research and teaching as a professor working in developmental immunotoxicology, immunology and immunogenetics. For over 20 years, he has served as a consultant to federal agencies as well as pharmaceutical, biotechnological, chemical and agricultural sector industries. Dr Dietert also directed Cornell’s toxicology institute (ICET), its breast cancer program (BCERF) and the training program of its NIEHS Superfund Program (SBREP). His expertise in developmental immunotoxicology (DIT) and health risk assessment is reflected in his more than 150 peer-reviewed research papers, and he is recognized in Who’s Who in the World, America and Medicine and Healthcare. He is among the first to have demonstrated differential immunotoxic susceptibilities among distinct gestational windows of development in the fetus. Dr. Dietert has both founded a scientific review journal and served as editor of a comparative immunology book series. He brings his expertise in age-related Immunotoxicity, immune evaluation strategies and health risk assessment to BRT in the establishment of a formal DIT screening program.
Brian C. Gilger, DVM, MS, Dipl. ACVO Director, Ophthalmic Toxicology
Dr. Gilger is Consulting Director of Ophthalmic Toxicology and Pharmacology Studies at BRT. He is a board-certified veterinary ophthalmologist, a Professor of Ophthalmology at North Carolina State University, and founder of Ophthalmic Consulting and Research, LLC, a company dedicated to the preclinical design and testing of ophthalmic pharmaceuticals and products for industry. Dr. Gilger has over 14 years experience in the design and completion of ophthalmic studies and has expertise in ocular toxicology, pharmacology and immunology. He has presented and published numerous ophthalmic studies, including those on ocular drug delivery devices, ocular immunology and ocular clinical trials. Dr. Gilger is on the editorial review board of the American Journal of Veterinary Research and Veterinary Ophthalmology and a scientific reviewer for Investigative Ophthalmology and Visual Science. Preclinical ophthalmic toxicology and pharmacology studies, both GLP and non-GLP, are conducted by Dr. Gilger at Burleson Research Technologies.
Gerald A. Denys, Ph.D., D(ABMM) Director, Microbiological Services Dr. Denys is Consulting Director of Microbiology Services at BRT and has over 20 years experience in clinical microbiology. This experience includes clinical appointments as Director of Microbiology at Sinai Hospital of Detroit and Methodist Hospital in Indianapolis, diagnostic experience as Principal Investigator for numerous clinical trials, and pharmaceutical experience as Consulting Microbiologist for new drug development. Dr. Denys is board certified as a Diplomate of the American Board of Medical Microbiology (ASM). He has experience with multidisciplinary teams in the development of new compounds. Dr. Denys directs microbiology studies at BRT, including antimicrobial testing, compound screening and bacterial identification.
Paul Struve Study Director Paul Struve has over 32 years of experience in pharmaceutical toxicology. This includes 14 years of service as a GLP Study Director at two major pharmaceutical companies. He has served as a toxicology representative on pharmaceutical drug development project teams, Study Monitor for GLP studies conducted at CROs, Safety Pharmacologist, and telemetry pharmacologist/toxicologist. He also has extensive experience in electrocardiography, cardiovascular pharmacology/toxicology, general toxicology, and physiology.
HOME l ABOUT US l SERVICES l CONTACT US
120 First Flight Lane, Morrisville NC 27560 Phone:(919) 719-2500 Fax:(919) 719-2505 E-mail: info@brt-labs.com |
